Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/9/2018
Start Date:September 2013
End Date:September 2019
Contact:Edwin Thomas
Email:clinical@eleison-pharma.com
Phone:215 554 3530

Use our guide to learn which trials are right for you!

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

The study is designed to assess whether glufosfamide provides additional survival benefit as
compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already
progressed or failed therapy on a gemcitabine based first line regimen.


Inclusion Criteria:

- At least 18 years of age

- Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology
(CT- or endoscopic-guided)

- Metastatic pancreatic cancer

- Disease progression during or after treatment with gemcitabine (alone or in
combination with other agents; at regular, not radiosensitizing, doses)

- Measurable or nonmeasurable disease by RECIST criteria (at least one target or
nontarget lesion)

- Recovered from reversible toxicities of prior therapy

- ECOG performance status 0-1

- All women of childbearing potential and all men must agree to use effective means of
contraception (surgical sterilization or the use of barrier contraception with either
a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into
the study through 6 months after the last dose of chemotherapy

- Ability to understand the purposes and risks of the study and has signed a written
informed consent form approved by the investigator's IRB/Ethics Committee

Exclusion Criteria:

- More than one prior systemic therapy regimen for metastatic pancreatic cancer
(radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do
not count as a prior systemic therapy regimen)

- Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic
antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1

- Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with
oral glucose lowering agents and the occasional use of insulin are permitted in the
study)

- Symptomatic brain metastases (baseline CT scan is not required in asymptomatic
patients)

- Active clinically significant infection requiring antibiotics

- Known HIV positive or active hepatitis B or C

- Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or
4), particularly coronary artery disease, arrhythmias or conduction defects with risk
of cardiovascular instability, uncontrolled hypertension, clinically significant
pericardial effusion, or congestive heart failure

- No other active malignancies (other than treated non-melanoma skin cancer or treated
in situ cancer) within the past year

- Major surgery within 3 weeks of the start of study treatment, without complete
recovery

- Clinically significant abnormalities in laboratory test results (including complete
blood count, chemistry panel including electrolytes, and urinalysis)

- Hemoglobin <9 g/dL (may receive transfusion or erythropoietin to maintain)

- ANC <1500/μL

- Platelet count <100,000/μL

- Total bilirubin > 1.5×ULN

- AST/ALT > 2.5-fold above ULN (>5-fold above ULN if liver metastases)

- Phosphorus < LLN

- Potassium < LLN

- Serum creatinine > 2 mg/dL

- Creatinine clearance < 60 mL/min (calculated by Cockcroft-Gault formula)

- Females who are pregnant or breast-feeding

- Participation in an investigational drug or device study within 14 days of the first
day of dosing on this study

- Concomitant disease or condition that could interfere with the conduct of the study,
or that would, in the opinion of the investigator, pose an unacceptable risk to the
patient in this study

- Any medical history, concurrent disease or concomitant medication which could
reasonably predispose the patient to renal insufficiency while on study treatment

- Contraindication or unwillingness to undergo multiple CT scans

- Unwillingness or inability to comply with the study protocol for any other reason
We found this trial at
22
sites
Louisville, Kentucky 40207
Principal Investigator: Wanjian Zhong
Phone: 502-897-1166
?
mi
from
Louisville, KY
Click here to add this to my saved trials
3525
Lakeland, Florida 33805
Principal Investigator: Madhavi Venigalla, MD
Phone: 863-904-1877
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Marcus Noel, MD
Phone: 585-276-4448
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra Prow
Phone: 515-239-2684
?
mi
from
Ames, IA
Click here to add this to my saved trials
Arlington, Texas
Principal Investigator: Alfred DiStefano
Phone: 972-755-8076
?
mi
from
Arlington, TX
Click here to add this to my saved trials
Canton, Ohio 44718
Principal Investigator: Nashat Gabrail, MD
Phone: 330-417-8231
?
mi
from
Canton, OH
Click here to add this to my saved trials
Corona, California 92879
Principal Investigator: Rehana Baqai
Phone: 951-276-2760
?
mi
from
Corona, CA
Click here to add this to my saved trials
Fountain Valley, California 92708
Principal Investigator: Haresh S Jhangiani
Phone: 714-698-0300
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Indianapolis, Indiana 46254
Principal Investigator: Robert F Manges
Phone: 317-297-2208
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Knoxville, Tennessee 37909
Principal Investigator: David R Schumaker
Phone: 865-934-2672
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
Principal Investigator: Greggory Ripple, MD
Phone: 603-650-9474
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Los Angeles, California 90033
Principal Investigator: Hao Wei Zhang, MD
Phone: 424-208-8866
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Michael Guarino
Phone: 302-623-4638
?
mi
from
Newark, DE
Click here to add this to my saved trials
PIttsburgh, Pennsylvania 15212
Principal Investigator: Moses Raj
Phone: 412-491-1384
?
mi
from
PIttsburgh, PA
Click here to add this to my saved trials
Riverside, California 92501
Principal Investigator: Brian Choi
Phone: 951-276-2760
?
mi
from
Riverside, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Nishant Poddar, MD
Phone: 314-577-8916
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sparta, New Jersey 07871
Principal Investigator: Bohdan E Halibey, MD
Phone: 973-729-8801
?
mi
from
Sparta, NJ
Click here to add this to my saved trials
Springfield, Illinois 62702
Principal Investigator: Meghna Desai, MD
Phone: 217-545-7969
?
mi
from
Springfield, IL
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Richard Kim, MD
Phone: 813-745-1157
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Terre Haute, Indiana 47802
Principal Investigator: Ashis K Chakrabarti, MD
Phone: 812-234-0098
?
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Whittier, California 90603
Principal Investigator: Richy Agajanian, MD
Phone: 562-652-6532
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Worcester, Massachusetts 01608
Principal Investigator: Amr Hassan, MD
Phone: 508-556-5429
?
mi
from
Worcester, MA
Click here to add this to my saved trials